{"id":"fam-trastuzumab-deruxtecan-nxki-tdxd","_chembl":null,"allNames":"fam-trastuzumab deruxtecan-nxki (tdxd)","_dailymed":null,"mechanism":{"target":"HER2","drugClass":"Antibody-drug conjugate","explanation":"Fam-trastuzumab deruxtecan-nxki binds to the HER2 receptor on cancer cells, allowing the attached cytotoxic agent to enter the cell and trigger cell death, effectively targeting tumors that overexpress HER2.","oneSentence":"Fam-trastuzumab deruxtecan-nxki targets HER2-positive cancer cells, delivering a cytotoxic payload to induce apoptosis."},"_scrapedAt":"2026-03-28T01:47:42.265Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:45:50.161342+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT05274048","phase":"PHASE1","title":"Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2022-06-24","conditions":"Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Fam-Trastuzumab Deruxtecan-Nxki (TDxD)","genericName":"fam-trastuzumab-deruxtecan-nxki-tdxd","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":7,"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:45:50.161342+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}